diseases, autoimmune diseases, and severe pain. All the drugs, manufactured by the company are delivered to broad range of pharmaceutical companies, ranging from large global organizations to development stage companies. The company through its drug technologies has developed improved formulations of 35 products that were launched in over 100 countries. The company also markets its product, TYSABRI in United States, the European Union, Switzerland, Canada, and Australia. The company has its R&D, marketing and manufacturing located in Ireland and the U.S. Elan is headquartered in Dublin, Ireland.

Elan Pharmaceuticals, Inc was acquired by Perrigo Co. (PRGO), a U.S. maker of over-the-counter medicines, in 2013 for $8.6 billion, gaining a low-tax base for international expansion.